
Browsing restrictions can be lifted for a fee.
Level Biotechnology Inc. engages in marketing and distributing cell culture, immunology, and molecular biology products in Taiwan. It also markets and distributes biomedical precision equipment. In addition, the company provides services in the areas of mammalian and genetic toxicology, pharmacology, biocompatibility, and model animal production. Further, it offers preclinical research services to the biotech, pharmaceutical, medical device, animal health, and agrichemical industries. The company was founded in 1989 and is headquartered in New Taipei City, Taiwan.
3118
進階
-0.15%
(-0.00)
The most recent financial report for 進階 (3118) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 3118's short-term business performance and financial health. For the latest updates on 3118's earnings releases, visit this page regularly.
According to historical valuation range analysis, 進階 (3118)'s current price-to-earnings (P/E) ratio is 10.98, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
According to the latest financial report, 進階 (3118) reported an Operating Profit of 22.09M with an Operating Margin of 11.75% this period, representing a decline of 6.33% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, 進階 (3118) announced revenue of 188.03M, with a Year-Over-Year growth rate of -8.16%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
At the end of the period, 進階 (3118) held Total Cash and Cash Equivalents of 210.34M, accounting for 0.24 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, 進階 (3118) achieved the “three margins increasing” benchmark, with a gross margin of 34.97%%, operating margin of 11.75%%, and net margin of 9.77%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 3118's profit trajectory and future growth potential.
According to the past four quarterly reports, 進階 (3118)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 0.57. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
進階 (3118)'s Free Cash Flow (FCF) for the period is -931K, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 96.86% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.